Evidence Review

BPC-157

Verdict
Insufficient Data
Evidence Tier
D
Insufficient evidence
Human Studies
Fewer than 30 subjects total
Typical Cost
$100-200/mo
BPC-157 has generated excitement from animal studies showing gut healing and tissue repair. However, fewer than 30 humans have ever been studied in published research. One clinical trial was cancelled without explanation. The FDA banned BPC-157 from compounding pharmacies in 2024 due to safety concerns. The gap between animal promise and human evidence is enormous.

The full evidence review — including why fewer than 30 humans have been studied and what the FDA ban actually means — is in Section 4 (Peptides: The Wild West) of The Anti-Longevity Playbook.

Reviewed by Dr. Ramy Khalil, MD · Double Board-Certified Internal Medicine · Last updated March 2026

Is BPC-157 safe and effective?

Fewer than 30 humans have been studied in published research. The FDA banned it from compounding pharmacies in 2024. Animal data is interesting, but the human evidence gap is enormous.

Free Chapter

Want the full picture?
Start with a free chapter.

Read the first chapter of The Anti-Longevity Playbook free — including the intervention with stronger mortality data than BPC-157.

No spam. Just the free chapter.

More from Peptides: The Wild West